874472-98-7

Usage

Chemical Properties

Colorless to tan crystalline solid

Upstream product

• 1122-85-6 phenyl cyanate 
• 74-88-4 methyl iodide 
• 611-20-1 salicylonitrile 
• 13073-28-4 3-bromo-2-hydroxybenzonitrile 

Downstream Products

• 1202677-56-2 2-methoxy-3-pyridin-4-yl-benzonitrile 
• 791136-88-4 3-bromo-2-methoxybenzamide 
• 1202677-57-3 2-hydroxy-3-pyridin-4-yl-benzonitrile 
• 1202677-58-4 trifluoromethanesulfonic acid 2-cyano-6-pyridin-4-yl-phenyl ester 
• 1202661-18-4 6-pyridin-4-yl-4'-(quinolin-2-ylmethoxy)-biphenyl-2-carbonitrile 
• 874472-84-1 2-methoxy-3-(4, 4,5,5-tetramethyl-1,3, 2-dioxaborolan-2-yl)benzonitrile 
• 1301610-50-3 tert-butyl (1-(4-((3-cyano-2-methoxyphenyl)ethynyl)phenyl)cyclobutyl)carbamate 
• 1260021-80-4 3-bromo-N-hydroxy-2-(methyloxy)benzenecarboximidamide 
• 877159-73-4 (+/-)-5-chloro-6-(3-cyano-2-methoxyphenyl)-1,2,3,4-tetrahydro-2,2,4,8-tetramethylquinoline 

Relevant academic research and scientific papers

TYK2 INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.

As opioid receptor antagonists or inverse agonists of the novel compounds

Novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, pharmaceutical compositions containing them, to processes for their preparation.

DI-SUBSTITUTED PHENYL COMPOUNDS

Di-substituted phenyl compounds which are inhibitors of phosphodiesterase 10 are described as are processes, pharmaceutical compositions, pharmaceutical preparations and pharmaceutical use of the compounds in the treatment of mammals, including human(s) f